Federal Trade Commission v. AbbVie Inc, et al

  1. December 22, 2020

    The Biggest Rulings In Antitrust Cases Of 2020

    Over a dozen state-level enforcers lost their challenge of T-Mobile's merger with Sprint, the Federal Trade Commission suffered major appellate losses in its case against Qualcomm and in a generic drug case, and a private plaintiff scored a big win against Comcast in circuit court.

  2. December 04, 2020

    3rd Circ. Won't Rethink Nixing $448M AbbVie Penalty

    The full Third Circuit refused Friday to rethink a panel decision reversing a court-ordered $448 million penalty the Federal Trade Commission won against AbbVie and Besins for allegedly delaying generic forms of the testosterone treatment AndroGel through sham litigation.

  3. November 17, 2020

    FTC Urges 3rd Circ. To Restore $448M AbbVie Penalty

    The Federal Trade Commission asked the Third Circuit for a rehearing after a panel reversed a court-ordered $448 million penalty against AbbVie and Besins for allegedly delaying generic forms of the testosterone treatment AndroGel through sham litigation, saying the decision would give the companies and others like them "every incentive to repeat those violations."

  4. September 30, 2020

    3rd Circ. Wipes Out FTC's $448M AbbVie Win

    The Third Circuit on Wednesday reversed a court-ordered $448 million penalty against AbbVie and Besins for allegedly delaying generic forms of the testosterone treatment AndroGel through sham litigation, pointing to the U.S. Supreme Court's Liu decision while concluding the Federal Trade Commission lacked disgorgement authority.

  5. September 08, 2020

    FTC Says 3rd Circ. Ruling Can't Help AbbVie In AndroGel Case

    The Federal Trade Commission has urged the Third Circuit to ignore AbbVie Inc.'s assertion that a recent ruling involving alleged abuse of the litigation process supports the company's bid to evade claims that it used sham lawsuits to delay generic competition for its AndroGel testosterone treatment.

  6. August 31, 2020

    AbbVie Points 3rd Circ. To School Board Ruling In FTC Case

    AbbVie Inc. has told the Third Circuit that a recent ruling involving alleged abuse of the litigation process supports the company's bid to evade Federal Trade Commission claims that it delayed generic competition for its AndroGel testosterone treatment through sham lawsuits.

  7. July 27, 2020

    FTC, AbbVie Don't Want Spat Paused Amid Justices' Review

    The Federal Trade Commission and AbbVie separately told the Third Circuit on Friday there is no need to pause their antitrust spat while the U.S. Supreme Court reviews the agency's authority to order financial restitution, although both sides had different reasons for wanting the case to go forward.

  8. July 13, 2020

    3rd Circ. Mulling FTC-AbbVie Pause Till High Court Acts

    The Third Circuit may need to pump the brakes on the Federal Trade Commission's antitrust spat with AbbVie following a U.S. Supreme Court decision to review the agency's authority to order financial restitution, the Philadelphia appeals court said.

  9. June 25, 2020

    AbbVie, FTC Tussle Over High Court's View On Disgorgement

    AbbVie and the Federal Trade Commission are both pointing to a U.S. Supreme Court decision this week on securities fraud to boost their arguments in the Third Circuit over a $448 million disgorgement order against the drugmaker.

  10. January 30, 2020

    Feds, AbbVie Agree Drug Delay Case Belongs In 3rd Circ.

    Both the Federal Trade Commission and AbbVie have urged the Third Circuit not to move an antitrust case focused on delays to generic competition for AndroGel to the Federal Circuit simply because it implicates some issues of patent law.